## Aditya H Gaur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5573143/publications.pdf

Version: 2024-02-01

107 papers	5,214 citations	38 h-index	95266 68 g-index
110	110	110	6871 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. New England Journal of Medicine, 2021, 385, 595-608.	27.0	359
2	Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. Journal of Clinical Oncology, 2017, 35, 2082-2094.	1.6	337
3	Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2012, 30, 4427-4438.	1.6	311
4	PG4KDS: A model for the clinical implementation of preâ€emptive pharmacogenetics. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2014, 166, 45-55.	1.6	221
5	Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clinical Infectious Diseases, 2017, 65, 1819-1828.	5.8	179
6	Risk Factors for Severe Respiratory Syncytial Virus Disease in Children With Cancer: The Importance of Lymphopenia and Young Age. Pediatrics, 2008, 121, 235-243.	2.1	172
7	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real-World Implementation. Clinical Pharmacology and Therapeutics, 2013, 94, 207-210.	4.7	164
8	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>UGT1A1</i> and Atazanavir Prescribing. Clinical Pharmacology and Therapeutics, 2016, 99, 363-369.	4.7	161
9	Bacillus cereus Bacteremia and Meningitis in Immunocompromised Children. Clinical Infectious Diseases, 2001, 32, 1456-1462.	5.8	147
10	Etiology and Clinical Course of Febrile Neutropenia in Children With Cancer. Journal of Pediatric Hematology/Oncology, 2009, 31, 623-629.	0.6	145
11	Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation. JAMA - Journal of the American Medical Association, 2018, 320, 995.	7.4	136
12	Intravenous Zanamivir for Oseltamivir-Resistant 2009 H1N1 Influenza. New England Journal of Medicine, 2010, 362, 88-89.	27.0	128
13	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for <i>CYP2B6</i> and Efavirenzâ€Containing Antiretroviral Therapy. Clinical Pharmacology and Therapeutics, 2019, 106, 726-733.	4.7	125
14	The Use of Cell Phone Support for Non-adherent HIV-Infected Youth and Young Adults: An Initial Randomized and Controlled Intervention Trial. AIDS and Behavior, 2014, 18, 686-696.	2.7	95
15	Preventing CLABSIs Among Pediatric Hematology/Oncology Inpatients: National Collaborative Results. Pediatrics, 2014, 134, e1678-e1685.	2.1	89
16	The Use and Abuse of Antibiotics and the Development of Antibiotic Resistance. Advances in Experimental Medicine and Biology, 2010, 659, 73-82.	1.6	87
17	Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a Routinely Screened Workforce. JAMA - Journal of the American Medical Association, 2021, 325, 2500.	7.4	83
18	Difference in Time to Detection: A Simple Method to Differentiate Catheter-Related from Nonâ€"Catheter-Related Bloodstream Infection in Immunocompromised Pediatric Patients. Clinical Infectious Diseases, 2003, 37, 469-475.	5.8	80

#	Article	IF	CITATIONS
19	Practice of Feeding Premasticated Food to Infants: A Potential Risk Factor for HIV Transmission. Pediatrics, 2009, 124, 658-666.	2.1	74
20	Motivating factors for high rates of influenza vaccination among healthcare workers. Vaccine, 2011, 29, 5963-5969.	3.8	74
21	Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. Journal of Infectious Diseases, 2021, 224, 1581-1592.	4.0	72
22	Diagnosis of Catheter-Related Bloodstream Infections Among Pediatric Oncology Patients Lacking a Peripheral Culture, Using Differential Time to Detection. Pediatric Infectious Disease Journal, 2005, 24, 445-449.	2.0	66
23	Risk Prediction in Pediatric Cancer Patients With Fever and Neutropenia. Pediatric Infectious Disease Journal, 2010, 29, 53-59.	2.0	66
24	Aging and Loss to Follow-up Among Youth Living With Human Immunodeficiency Virus in the HIV Research Network. Journal of Adolescent Health, 2015, 56, 345-351.	2.5	64
25	Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia. Clinical Infectious Diseases, 2017, 65, 1790-1798.	5.8	62
26	Early Archiving and Predominance of Nonnucleoside Reverse Transcriptase Inhibitor–Resistant HIVâ€1 among Recently Infected Infants Born in the United States. Journal of Infectious Diseases, 2007, 195, 1402-1410.	4.0	58
27	The HIV Care Continuum: Changes over Time in Retention in Care and Viral Suppression. PLoS ONE, 2015, 10, e0129376.	2.5	56
28	Catheter Design Influences Recurrence of Catheter-Related Bloodstream Infection in Children With Cancer. Journal of Clinical Oncology, 2003, 21, 3520-3525.	1.6	55
29	Implementation of and Barriers to Routine HIV Screening for Adolescents. Pediatrics, 2009, 124, 1076-1084.	2.1	54
30	Central Line Associated Blood Stream Infections in Pediatric Hematology/Oncology Patients With Different Types of Central Lines. Pediatric Blood and Cancer, 2016, 63, 1603-1607.	1.5	54
31	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer, 2014, 120, 1985-1992.	4.1	53
32	In Situ Diagnosis of Central Venous Catheter-Related Bloodstream Infection Without Peripheral Blood Culture. Pediatric Infectious Disease Journal, 2004, 23, 614-618.	2.0	52
33	Provider and Practice Characteristics Associated With Antibiotic Use in Children With Presumed Viral Respiratory Tract Infections. Pediatrics, 2005, 115, 635-641.	2.1	51
34	Interest of Youth Living With HIV in Long-Acting Antiretrovirals. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 190-197.	2.1	48
35	Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infectious Diseases, The, 2020, 20, 964-975.	9.1	47
36	Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Pediatric Infectious Disease Journal, 2013, 32, i.	2.0	46

3

#	Article	IF	Citations
37	Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. Lancet Infectious Diseases, The, 2018, 18, 854-863.	9.1	43
38	The Impact of Youth-Friendly Structures of Care on Retention Among HIV-Infected Youth. AIDS Patient Care and STDs, 2016, 30, 170-177.	2.5	42
39	Antimicrobial Stewardship Barriers and Goals in Pediatric Oncology and Bone Marrow Transplantation: A Survey of Antimicrobial Stewardship Practitioners. Infection Control and Hospital Epidemiology, 2016, 37, 343-347.	1.8	39
40	Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine, 2008, 26, 6883-6893.	3.8	38
41	Infections in children and young adults with bone malignancies undergoing limb-sparing surgery. Cancer, 2005, 104, 602-610.	4.1	37
42	Prospective Detection of Respiratory Pathogens in Symptomatic Children With Cancer. Pediatric Infectious Disease Journal, 2013, 32, e99-e104.	2.0	37
43	Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children. Vaccine Journal, 2015, 22, 298-303.	3.1	34
44	Optimizing blood culture practices in pediatric immunocompromised patients: evaluation of media types and blood culture volume. Pediatric Infectious Disease Journal, 2003, 22, 545-552.	2.0	31
45	Delayed Entry into and Failure to Remain in HIV Care Among HIV-Infected Adolescents. AIDS Research and Human Retroviruses, 2013, 29, 99-104.	1.1	30
46	Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV,the, 2016, 3, e561-e568.	4.7	30
47	Disparities in Antiretroviral Treatment: A Comparison of Behaviorally HIV-Infected Youth and Adults in the HIV Research Network. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 100-107.	2.1	29
48	Premastication as a Route of Pediatric HIV Transmission. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 207-212.	2.1	29
49	Does It Really Take Longer Not to Prescribe Antibiotics for Viral Respiratory Tract Infections in Children?. Academic Pediatrics, 2006, 6, 152-156.	1.7	28
50	Predictors of Highly Active Antiretroviral Therapy Utilization for Behaviorally HIV-1–Infected Youth: Impact of Adult Versus Pediatric Clinical Care Site. Journal of Adolescent Health, 2012, 50, 471-477.	<b>2.</b> 5	26
51	The Impact of Vaccine Concerns on Racial/Ethnic Disparities in Influenza Vaccine Uptake Among Health Care Workers. American Journal of Public Health, 2015, 105, e35-e41.	2.7	26
52	THE EXPANDING SPECTRUM OF DISEASES CAUSED BY BACILLUS CEREUS. Pediatric Infectious Disease Journal, 2001, 20, 533-534.	2.0	25
53	PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2. MSphere, 2022, 7, e0017922.	2.9	25
54	Directly Observed Therapy (DOT) for Nonadherent HIV-Infected Youth: Lessons Learned, Challenges Ahead. AIDS Research and Human Retroviruses, 2010, 26, 947-953.	1.1	23

#	Article	IF	CITATIONS
55	Psychological Factors, Beliefs About Medication, and Adherence of Youth With Human Immunodeficiency Virus in a Multisite Directly Observed Therapy Pilot Study. Journal of Adolescent Health, 2011, 48, 637-640.	2.5	23
56	Evaluating Application of the National Healthcare Safety Network Central Line—Associated Bloodstream Infection Surveillance Definition: A Survey of Pediatric Intensive Care and Hematology/Oncology Units. Infection Control and Hospital Epidemiology, 2013, 34, 663-670.	1.8	23
57	A Prospective, Holistic, Multicenter Approach to Tracking and Understanding Bloodstream Infections in Pediatric Hematology-Oncology Patients. Infection Control and Hospital Epidemiology, 2017, 38, 690-696.	1.8	23
58	Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial. The Lancet Child and Adolescent Health, 2017, 1, 27-34.	<b>5.</b> 6	22
59	The judicious use of antibiotics—An investment towards optimized health care. Indian Journal of Pediatrics, 2006, 73, 343-350.	0.8	21
60	Title is missing!. Pediatric Infectious Disease Journal, 2003, 22, 545-552.	2.0	20
61	Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 135-139.	2.1	20
62	Liver Enzyme Elevations in Plasmodium falciparum Volunteer Infection Studies: Findings and Recommendations. American Journal of Tropical Medicine and Hygiene, 2020, 103, 378-393.	1.4	20
63	Optimum management of pediatric patients with fever and neutropenia. Indian Journal of Pediatrics, 2004, 71, 825-835.	0.8	18
64	Outcomes after bloodstream infection in hospitalized pediatric hematology/oncology and stem cell transplant patients. Pediatric Blood and Cancer, 2019, 66, e27978.	1.5	18
65	LEGIONELLA BOZEMANII PULMONARY ABSCESS IN A PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT RECIPIENT. Pediatric Infectious Disease Journal, 2007, 26, 760-762.	2.0	17
66	Development of a Directly Observed Therapy Adherence Intervention for Adolescents with Human Immunodeficiency Virus–1: Application of Focus Group Methodology to Inform Design, Feasibility, and Acceptability. Journal of Adolescent Health, 2009, 44, 124-132.	2.5	17
67	Surveillance of Hospital-Acquired Central Line–Associated Bloodstream Infections in Pediatric Hematology-Oncology Patients Lessons Learned, Challenges Ahead. Infection Control and Hospital Epidemiology, 2013, 34, 315-320.	1.8	17
68	Trends in Hospitalizations Among Children and Young Adults with Perinatally Acquired HIV. Pediatric Infectious Disease Journal, 2014, 33, 488-494.	2.0	17
69	Pre-vaccination prevalence of anogenital and oral human papillomavirus in young HIV-infected men who have sex with men. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 52-61.	4.5	17
70	High Prevalence of Anal High-Grade Squamous Intraepithelial Lesions, and Prevention Through Human Papillomavirus Vaccination, in Young Men Who Have Sex With Men Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, 1388-1396.	5 <b>.</b> 8	17
71	A Randomized, Open-Label Study of the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate in HIV-1–infected Children With Virologic Suppression. Pediatric Infectious Disease Journal, 2015, 34, 376-382.	2.0	16
72	Mucosal barrier injury–associated bloodstream infections in pediatric oncology patients. Pediatric Blood and Cancer, 2020, 67, e28234.	1.5	15

#	Article	IF	CITATIONS
73	Incidence of and risk factors for community acquired pneumonia in US HIV-infected children, 2000–2005. Aids, 2011, 25, 717-720.	2.2	14
74	Severe H1N1â€associated acute respiratory failure in immunocompromised children. Pediatric Blood and Cancer, 2011, 57, 625-628.	1.5	14
75	Prospective evaluation for respiratory pathogens in children with sickle cell disease and acute respiratory illness. Pediatric Blood and Cancer, 2014, 61, 507-511.	1.5	14
76	An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization. Microbiology Spectrum, 2021, 9, e0105921.	3.0	14
77	Conformity of Pediatric/Adolescent HIV Clinics to the Patient-Centered Medical Home Care Model. AIDS Patient Care and STDs, 2013, 27, 272-279.	2.5	13
78	A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. Vaccine, 2018, 36, 214-219.	3.8	13
79	Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy. Open Forum Infectious Diseases, 2021, 8, ofab420.	0.9	12
80	Triggered Escalating Real-Time Adherence Intervention to Promote Rapid HIV Viral Suppression Among Youth Living With HIV Failing Antiretroviral Therapy: Protocol for a Triggered Escalating Real-Time Adherence Intervention. JMIR Research Protocols, 2019, 8, e11416.	1.0	12
81	Knowledge and Practice of Prechewing/Prewarming Food by HIV-Infected Women. Pediatrics, 2011, 127, e1206-e1211.	2.1	11
82	Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age. Clinical Infectious Diseases, 2020, 71, 1281-1288.	5.8	10
83	Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial. The Lancet Child and Adolescent Health, 2021, 5, 642-651.	5.6	10
84	Host Predictors of Broadly Cross-Reactive Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern Differ Between Infection and Vaccination. Clinical Infectious Diseases, 2022, 75, e705-e714.	5.8	10
85	Uptake and virological outcomes of single†versus multiâ€tablet antiretroviral regimens among treatmentâ€naà ve youth in the ⟨scp⟩HIV⟨/scp⟩ Research Network. HIV Medicine, 2019, 20, 169-174.	2.2	9
86	Effective Treatment of Cerebral Mucormycosis Associated with Brain Surgery. Pediatric Infectious Disease Journal, 2015, 34, 542-543.	2.0	7
87	Characterizing Body Image in Youth with HIV. AIDS and Behavior, 2016, 20, 1585-1590.	2.7	6
88	Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161). JMIR Research Protocols, 2019, 8, e9898.	1.0	6
89	Prechewing and Prewarming Food for HIV-Exposed Children: A Prospective Cohort Experience from Latin America. AIDS Patient Care and STDs, 2013, 27, 142-145.	2.5	5
90	Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5

#	Article	IF	Citations
91	Modeling Adherence Interventions Among Youth with HIV in the United States: Clinical and Economic Projections. AIDS and Behavior, 2021, 25, 2973-2984.	2.7	5
92	Randomized Controlled Trial of a Remote Coaching mHealth Adherence Intervention in Youth Living with HIV. AIDS and Behavior, 2022, 26, 3897-3913.	2.7	5
93	Antiretroviral Therapy in HIV-Infected Infants and Children. Pediatric Infectious Disease Journal, 2010, 29, 360-363.	2.0	4
94	Pause, Listen, Share. JAMA - Journal of the American Medical Association, 2014, 312, 345.	7.4	4
95	The impact of the <i>UGT1A1*60</i> allele on bilirubin serum concentrations. Pharmacogenomics, 2017, 18, 5-16.	1.3	4
96	Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development. EBioMedicine, 2022, 80, 104065.	6.1	4
97	Initial Management of Fever and Neutropenia in a Child With Cancerâ€"The Past, the Present, and the Future. Clinical Pediatric Emergency Medicine, 2011, 12, 174-184.	0.4	3
98	Correlates of High HIV Viral Load and Antiretroviral Therapy Adherence Among Viremic Youth in the United States Enrolled in an Adherence Improvement Intervention. AIDS Patient Care and STDs, 2021, 35, 145-157.	2.5	3
99	An adaptive, asymptomatic SARS-CoV-2 workforce screening program providing real-time, actionable monitoring of the COVID-19 pandemic. PLoS ONE, 2022, 17, e0268237.	2.5	3
100	Use of Placebo Pills Before Treatment Initiation in Youth with HIV: Are They Ready?. Journal of the International Association of Providers of AIDS Care, 2017, 16, 412-417.	1.5	2
101	Body Image and Risk Behaviors in Youth with HIV. AIDS Patient Care and STDs, 2017, 31, 176-181.	2.5	2
102	Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis Among Adolescent Girls. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 944-950.	2.1	2
103	Preventing Medication Nonadherence of Youth (13–24ÂYears) With HIV Initiating Antiretroviral Therapy. Journal of Adolescent Health, 2021, 69, 644-652.	2.5	2
104	Optimizing Frequency of CD4 Assays in the Era of Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2013, 29, 418-422.	1.1	1
105	A nucleic acid amplification testâ€based strategy does not help inform return to work for healthcare workers with COVIDâ€19. Influenza and Other Respiratory Viruses, 2022, 16, 851-853.	3.4	1
106	Discontinuity in Medicaid Coverage Among Young Adults with HIV. AIDS Patient Care and STDs, 2019, 33, 89-92.	2.5	0
107	Burden of bloodstream infections among ambulatory pediatric hematology/oncology patients with a central line Journal of Clinical Oncology, 2016, 34, 262-262.	1.6	0